胰高血糖素样肽-1受体激动剂与骨折风险:随机临床试验的网络Meta分析
该网络Meta分析纳入54项随机对照试验共49,602例2型糖尿病患者,评估GLP-1受体激动剂对骨折风险的影响。与安慰剂相比,艾塞那肽骨折风险最低(RR 0.17,95%CI 0.03-0.67),成为骨折风险最安全选项的概率最高。贝叶斯网络Meta分析提示GLP-1受体激动剂与骨折风险降低相关。
要点
- 纳入54项RCT共49,602例2型糖尿病患者,其中28,353例接受GLP-1受体激动剂治疗。
- 与安慰剂相比,艾塞那肽骨折风险最低(RR 0.17,95%CI 0.03-0.67)。
- 艾塞那肽成为骨折风险最安全选项的概率最高,其后依次为度拉糖肽、利拉鲁肽、阿必鲁肽、利司那肽和司美格鲁肽。
核心结论
- 贝叶斯网络Meta分析提示,在2型糖尿病患者中,与安慰剂或其他降糖药物使用者相比,GLP-1受体激动剂与骨折风险降低相关。
- 作者认为艾塞那肽是骨折风险方面的最佳选择药物。
研究设计与样本
- 本研究为网络Meta分析,检索电子数据库及ClinicalTrials.gov未发表研究,纳入54项随机对照试验共49,602例参与者,其中28,353例接受GLP-1受体激动剂治疗。
- 分析使用STATA 12.0和R软件(版本3.4.4),合并各试验骨折效应的RR及95%CI。
- 研究注册于PROSPERO(CRD42018094433)。
主要发现
- 与安慰剂相比,艾塞那肽骨折风险最低(RR 0.17,95%CI 0.03-0.67)。
- 艾塞那肽成为骨折风险最安全选项的概率最高(0.07‰),其后依次为度拉糖肽(1.04%)、利拉鲁肽(1.39%)、阿必鲁肽(5.61%)、利司那肽(8.07%)和司美格鲁肽(18.72%)。
- 部分比较中观察到统计学显著的不一致性。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 部分比较中观察到统计学显著的不一致性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Our network meta-analysis analyzed the effects of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) on fracture risk. By combining data from randomized controlled trials, we found that GLP-1 RAs were associated with a decreased bone fracture risk, and exenatide is the best option agent with regard to the risk of fracture. This study is registered with PROSPERO (CRD42018094433). INTRODUCTION: Data on the effects of GLP-1 RAs on fracture risk are conflicted. This study aimed to analyze the available evidence on the effects of GLP-1 RAs on fracture risk in type 2 diabetes mellitus patients. METHODS: Electronic databases were searched for relevant published articles, and unpublished studies presented at ClinicalTrials.gov were searched for relevant clinical data. All analyses were performed with STATA 12.0 and R software (Version 3.4.4). We estimated the risk ratio (RR) and 95% confidence interval (CI) by combining RRs for fracture effects of included trials. RESULTS: There were 54 eligible random control trials (RCTs) with 49,602 participants, including 28,353 patients treated with GLP-1 RAs. Relative to placebo, exenatide (RR, 0.17; 95% CI 0.03-0.67) was associated with lowest risk of fracture among other GLP-1 RAs. Exenatide had the highest probability to be the safest option with regard to the risk of fracture (0.07 ‰), followed by dulaglutide (1.04%), liraglutide (1.39%), albiglutide (5.61%), lixisenatide (8.07%), and semaglutide (18.72%). A statistically significant inconsistency was observed in some comparisons. CONCLUSION: The Bayesian network meta-analysis suggests that GLP-1 RAs were associated with a decreased bone fracture risk compared to users of placebo or other anti-hyperglycemic drugs in type 2 diabetes mellitus patients, and exenatide is the best option agent with regard to the risk of fracture.
引用
- Zhang YS, Weng WY, Xie BC, et al. Glucagon-like peptide-1 receptor agonists and fracture risk: a network meta-analysis of randomized clinical trials. Osteoporos Int. 2018. PMID: 30083774. doi:10.1007/s00198-018-4649-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。